Key Summary
- Industry leaders report a distinct mix of optimism, anticipation, and nervousness regarding day-one prescribing responsibilities.
- An estimated 2,600 pharmacists joining the GPhC register from September 2026 will have independent prescribing rights from the point of registration.
- Industry leaders share concerns about workplace readiness and infrastructural support
UK’s pharmacy industry is facing a significant milestone as newly qualified pharmacy students will qualify as day-one independent prescribers upon registration this September.
Industry leaders report immense excitement around the General Pharmaceutical Council (GPhC) reformed 2021 initial education and training standards.
It represented the biggest reform to pharmacy education and workforce development in Great Britain in decades.
The primary milestone driving industry attention is that, from the 2025/2026 graduating cohort onwards, newly qualified pharmacists will register as independent prescribers from Day 1.
However, significant concerns remain over the level of structural support available for new prescribers.
Samiha Amin, External Relations Officer BPSA, said that the biggest concern among newly qualified prescribers is the expectation to “take on greater clinical responsibility” without having enough protected time to continue developing their prescribing skills.
“Many students worry that the realities of a busy pharmacy could make it difficult to reflect on cases, seek advice or consolidate learning. Protected learning time is essential if independent prescribing is to be introduced safely and sustainably and many students feel this needs to be built into workforce planning rather than relying on individuals to learn in their own time,” she said.
Faith Adebimpe, founder of career coaching organisation Pharmacist Evolve, told Pharmacy Business that the change is a significant and positive step for the profession, but that sufficient support needs to be put in place by employers.
“An IP annotation on the register should be seen as the beginning of a pharmacist’s prescribing journey, rather than evidence that they are ready to prescribe independently in every clinical setting from day one,” she said.
Adebimpe shared concerns that intense operational pressures inside community pharmacies might force some pharmacists to move too quickly from supervised environments into high-volume clinical decision-making.
“Community pharmacy needs a structured transition model that builds confidence and competence progressively, rather than assuming that registration as an IP automatically translates into readiness for every service.”
To ensure that this newly qualified cohort of pharmacist’s transition remains safe and sustainable, she stressed that newly qualified pharmacist prescribers will require protected learning time, a named and accessible prescribing supervisor or mentor, a clearly defined scope of practice, regular case-based discussions and robust escalation routes, along with “genuine” access to the wider primary care team.
Infrastructure for new prescribers
Sarah Baig, Associate Professor and Prescribing Lead at the University of Birmingham School of Pharmacy, said registration and the start of pharmacy practice must be framed as the start of supported clinical practice, not the end of training.
“Newly qualified pharmacist prescribers should have clearly documented scopes of practice, structured mentorship and supervision, access to patient records, robust referral pathways, and protected time for reflection and case review,” she said.
“This is particularly important in community pharmacy, where presentations are undifferentiated and patients may present before seeing any other clinician.”
Baig stressed the need for employers, commissioners, regulators and the wider NHS to build the clinical infrastructure for new prescribers.
“With it, this reform can be transformative for access, prevention, medicines optimisation and patient safety,” she said.
Baig also spoke to Pharmacy Business regarding the shortage of Designated Prescribing Practitioners (DPPs).
She said: “The shortage of Designated Prescribing Practitioners is one of the most urgent workforce issues facing pharmacy education. It is also a predictable consequence of trying to scale prescribing faster than we have scaled the supervision model.
“The answer cannot simply be to ask the same small group of experienced prescribers to do more. Supervision must be recognised as a core part of clinical workforce development, not a goodwill activity squeezed into already pressured roles.
She stressed the need for a funded, structured, and multi-professional DPP model.
Reactions from the industry
Speaking to Pharmacy Business, Mohamed Demiry, a trainee pharmacist at Lindsay & Gilmour Pharmacy, said that he feels more nervous than excited but he stresses that he feels ready.
“I do feel ready to be a pharmacist and gradually use my prescribing while expanding my scope by extra learning and clinical training,” he said.
He added, “I think that we will need serious change in the community pharmacist access to patient records and referral system to make the most out of prescribing in community.”
Abdullah Mekky, Northern Area Coordinator for the British Pharmaceutical Students’ Association, said that there is a bit of uncertainty about how it would work among students as well as placement providers for post qualifying.
“Having the qualification as an IP means that one is theoretically competent however, in reality that might be different. With that being said, employers should act and put measures to prevent mistakes from happening and newly qualified pharmacists have to handle the privilege they have been given responibly and be aware of the risks associated with it,” he added.
Internationally trained pharmacists
Adebimpe added that for internationally trained pharmacists, there is an additional dimension of integration.
“Many will bring substantial clinical experience and prescribing capability from their home countries but may still need tailored support to navigate the UK’s particular systems: local referral pathways, documentation expectations, clinical communication, risk management, GP interfaces, NHS prescribing processes, and the cultural confidence required to challenge, escalate and make decisions in a new healthcare environment.”
She urged employers to recognise that internationally trained pharmacists may require additional support.
She said: “Employers need to recognise that internationally trained pharmacists may require a more intentional onboarding and mentorship model, with mentors who understand the transition process and can support both clinical development and integration into UK practice.”
“Ultimately, the question is not whether internationally trained pharmacists can become safe, capable prescribers. They absolutely can.
“The question is whether we are building workplaces and systems that allow them, and all newly qualified IPs, to develop safely rather than simply expecting them to cope.”
Gaps in supervision
Earlier this year, the Nuffield Trust warned that the induction of pharmacist independent prescribers to the NHS could be undermined by gaps in supervision, training and workforce planning.
In its report, the organisation pointed out these shortcomings could put the government plans to shift more care into community settings at risk.
In August, the National Pharmacy Association (NPA) unveiled a programme to support independent prescribing in community pharmacy.
